Skip to main content

Around 30 centres and hospitals in Catalonia are studying promising treatments of COVID-19

5 May 20

Images

Participants

Contact

Image
Press & Communications Section Head
Tel.+34 93 40 37255

The “Corporación Catalana de Medios Audiovisuales” has published a report on the RiPCoN project, in which IRB Barcelona’s Structural Bioinformatics and Network Biology is participating. Headed by Patrick Aloy, this lab is conducting a computational study of the interactions between the coronavirus and human cells with the aim to identify drugs already on the market or under development that can tackle the spread of the virus. The goal is to identify an antiviral treatment and, in the long-term, a possible vaccine.

In addition, various media have reported on  the efforts made by IRB Barcelona to conduct mass screening for the disease.

Link to: CCMA

Link to: CCMA

Link to: La Vanguardia

Link to: ABC

 

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).